Preventing tuberculosis in children with and without HIV
Official title: TUBERCULOSIS PREVENTION IN CHILDREN TWO TO LESS THAN 13 YEARS OF AGE WITH AND WITHOUT HIV
Funded at Westat, INC. · NIH-10872953 · Data updated 2026-11-12
This study is looking at how well a daily combination of two medicines, Rifapentine and Isoniazid, can help prevent tuberculosis in children aged 2 to under 13, especially those living with HIV, and it will check how safe and easy the treatment is for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Westat, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2027 |
| Funding year | 2023 |
| Award (this year) | $2,220,803 |
| NIH project number | 75N94023D00001-0-759402300002-1 |
| Project ID | NIH-10872953 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children aged two to less than 13 years, both with and without HIV.
✕Less likely to help
Patients outside the specified age range or those without a risk of tuberculosis may not benefit from this research.
What this research studies
This research investigates the effectiveness of a combination of daily Rifapentine and Isoniazid for preventing tuberculosis in children aged two to less than 13 years, including those living with HIV. The study aims to determine the appropriate dosage, safety, and tolerability of this treatment regimen. By participating, children will be monitored closely to assess how well the medication works and any side effects that may occur. The research is part of a larger initiative to improve health outcomes for vulnerable populations, particularly in the context of HIV.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of tuberculosis in children, especially those at higher risk due to HIV.
How similar studies have gone: Previous research has shown promise in using similar drug combinations for tuberculosis prevention, indicating potential for success in this approach.
Where this research is happening
-
Westat, INC.
Rockville, United States Active
Researchers
- Principal investigator: Driver, Barbara — Westat, INC.
- Study coordinator: Driver, Barbara
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.